Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested usi...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tezcan, Gulcin [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
11 |
|---|
| Übergeordnetes Werk: |
Enthalten in: A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a - Liao, Gary ELSEVIER, 2020, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:90 ; year:2017 ; pages:713-723 ; extent:11 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.biopha.2017.04.022 |
|---|
| Katalog-ID: |
ELV015178218 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV015178218 | ||
| 003 | DE-627 | ||
| 005 | 20230625114642.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2017.04.022 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000092A.pica |
| 035 | |a (DE-627)ELV015178218 | ||
| 035 | |a (ELSEVIER)S0753-3322(17)30781-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.86 |2 bkl | ||
| 100 | 1 | |a Tezcan, Gulcin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 11 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. | ||
| 520 | |a Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. | ||
| 650 | 7 | |a VEGFA |2 Elsevier | |
| 650 | 7 | |a Angiogenesis |2 Elsevier | |
| 650 | 7 | |a MMP2 |2 Elsevier | |
| 650 | 7 | |a Olea europaea leaf extract |2 Elsevier | |
| 650 | 7 | |a MMP9 |2 Elsevier | |
| 650 | 7 | |a Invasion |2 Elsevier | |
| 650 | 7 | |a Glioblastoma cancer stem cell |2 Elsevier | |
| 700 | 1 | |a Taskapilioglu, Mevlut Ozgur |4 oth | |
| 700 | 1 | |a Tunca, Berrin |4 oth | |
| 700 | 1 | |a Bekar, Ahmet |4 oth | |
| 700 | 1 | |a Demirci, Hilal |4 oth | |
| 700 | 1 | |a Kocaeli, Hasan |4 oth | |
| 700 | 1 | |a Aksoy, Secil Ak |4 oth | |
| 700 | 1 | |a Egeli, Unal |4 oth | |
| 700 | 1 | |a Cecener, Gulsah |4 oth | |
| 700 | 1 | |a Tolunay, Sahsine |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Liao, Gary ELSEVIER |t A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |d 2020 |g Amsterdam [u.a.] |w (DE-627)ELV004620771 |
| 773 | 1 | 8 | |g volume:90 |g year:2017 |g pages:713-723 |g extent:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.biopha.2017.04.022 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.86 |j Hämatologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 90 |j 2017 |h 713-723 |g 11 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
g t gt |
|---|---|
| matchkey_str |
tezcangulcintaskapilioglumevlutozgurtunc:2017----:lauoaaefxrcadeaiuasnritclyxiibnfcaefccuohmnlolsoaacrtmeltr |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.86 |
| publishDate |
2017 |
| allfields |
10.1016/j.biopha.2017.04.022 doi GBV00000000000092A.pica (DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Tezcan, Gulcin verfasserin aut Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier Taskapilioglu, Mevlut Ozgur oth Tunca, Berrin oth Bekar, Ahmet oth Demirci, Hilal oth Kocaeli, Hasan oth Aksoy, Secil Ak oth Egeli, Unal oth Cecener, Gulsah oth Tolunay, Sahsine oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:713-723 extent:11 https://doi.org/10.1016/j.biopha.2017.04.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 713-723 11 045F 610 |
| spelling |
10.1016/j.biopha.2017.04.022 doi GBV00000000000092A.pica (DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Tezcan, Gulcin verfasserin aut Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier Taskapilioglu, Mevlut Ozgur oth Tunca, Berrin oth Bekar, Ahmet oth Demirci, Hilal oth Kocaeli, Hasan oth Aksoy, Secil Ak oth Egeli, Unal oth Cecener, Gulsah oth Tolunay, Sahsine oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:713-723 extent:11 https://doi.org/10.1016/j.biopha.2017.04.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 713-723 11 045F 610 |
| allfields_unstemmed |
10.1016/j.biopha.2017.04.022 doi GBV00000000000092A.pica (DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Tezcan, Gulcin verfasserin aut Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier Taskapilioglu, Mevlut Ozgur oth Tunca, Berrin oth Bekar, Ahmet oth Demirci, Hilal oth Kocaeli, Hasan oth Aksoy, Secil Ak oth Egeli, Unal oth Cecener, Gulsah oth Tolunay, Sahsine oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:713-723 extent:11 https://doi.org/10.1016/j.biopha.2017.04.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 713-723 11 045F 610 |
| allfieldsGer |
10.1016/j.biopha.2017.04.022 doi GBV00000000000092A.pica (DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Tezcan, Gulcin verfasserin aut Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier Taskapilioglu, Mevlut Ozgur oth Tunca, Berrin oth Bekar, Ahmet oth Demirci, Hilal oth Kocaeli, Hasan oth Aksoy, Secil Ak oth Egeli, Unal oth Cecener, Gulsah oth Tolunay, Sahsine oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:713-723 extent:11 https://doi.org/10.1016/j.biopha.2017.04.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 713-723 11 045F 610 |
| allfieldsSound |
10.1016/j.biopha.2017.04.022 doi GBV00000000000092A.pica (DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.86 bkl Tezcan, Gulcin verfasserin aut Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro 2017transfer abstract 11 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier Taskapilioglu, Mevlut Ozgur oth Tunca, Berrin oth Bekar, Ahmet oth Demirci, Hilal oth Kocaeli, Hasan oth Aksoy, Secil Ak oth Egeli, Unal oth Cecener, Gulsah oth Tolunay, Sahsine oth Enthalten in Elsevier Science Liao, Gary ELSEVIER A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a 2020 Amsterdam [u.a.] (DE-627)ELV004620771 volume:90 year:2017 pages:713-723 extent:11 https://doi.org/10.1016/j.biopha.2017.04.022 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.86 Hämatologie VZ AR 90 2017 713-723 11 045F 610 |
| language |
English |
| source |
Enthalten in A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Amsterdam [u.a.] volume:90 year:2017 pages:713-723 extent:11 |
| sourceStr |
Enthalten in A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a Amsterdam [u.a.] volume:90 year:2017 pages:713-723 extent:11 |
| format_phy_str_mv |
Article |
| bklname |
Hämatologie |
| institution |
findex.gbv.de |
| topic_facet |
VEGFA Angiogenesis MMP2 Olea europaea leaf extract MMP9 Invasion Glioblastoma cancer stem cell |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| authorswithroles_txt_mv |
Tezcan, Gulcin @@aut@@ Taskapilioglu, Mevlut Ozgur @@oth@@ Tunca, Berrin @@oth@@ Bekar, Ahmet @@oth@@ Demirci, Hilal @@oth@@ Kocaeli, Hasan @@oth@@ Aksoy, Secil Ak @@oth@@ Egeli, Unal @@oth@@ Cecener, Gulsah @@oth@@ Tolunay, Sahsine @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV004620771 |
| dewey-sort |
3610 |
| id |
ELV015178218 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015178218</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625114642.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biopha.2017.04.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000092A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015178218</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0753-3322(17)30781-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.86</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tezcan, Gulcin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGFA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Angiogenesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMP2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Olea europaea leaf extract</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMP9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Invasion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glioblastoma cancer stem cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taskapilioglu, Mevlut Ozgur</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tunca, Berrin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bekar, Ahmet</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Demirci, Hilal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kocaeli, Hasan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aksoy, Secil Ak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egeli, Unal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cecener, Gulsah</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tolunay, Sahsine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liao, Gary ELSEVIER</subfield><subfield code="t">A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004620771</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:713-723</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biopha.2017.04.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.86</subfield><subfield code="j">Hämatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2017</subfield><subfield code="h">713-723</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Tezcan, Gulcin |
| spellingShingle |
Tezcan, Gulcin ddc 610 bkl 44.86 Elsevier VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| authorStr |
Tezcan, Gulcin |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV004620771 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.86 bkl Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell Elsevier |
| topic |
ddc 610 bkl 44.86 Elsevier VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell |
| topic_unstemmed |
ddc 610 bkl 44.86 Elsevier VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell |
| topic_browse |
ddc 610 bkl 44.86 Elsevier VEGFA Elsevier Angiogenesis Elsevier MMP2 Elsevier Olea europaea leaf extract Elsevier MMP9 Elsevier Invasion Elsevier Glioblastoma cancer stem cell |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m o t mo mot b t bt a b ab h d hd h k hk s a a sa saa u e ue g c gc s t st |
| hierarchy_parent_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| hierarchy_parent_id |
ELV004620771 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV004620771 |
| title |
Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| ctrlnum |
(DE-627)ELV015178218 (ELSEVIER)S0753-3322(17)30781-3 |
| title_full |
Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| author_sort |
Tezcan, Gulcin |
| journal |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| journalStr |
A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
713 |
| author_browse |
Tezcan, Gulcin |
| container_volume |
90 |
| physical |
11 |
| class |
610 610 DE-600 610 VZ 44.86 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tezcan, Gulcin |
| doi_str_mv |
10.1016/j.biopha.2017.04.022 |
| dewey-full |
610 |
| title_sort |
olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| title_auth |
Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| abstract |
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. |
| abstractGer |
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. |
| abstract_unstemmed |
Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro |
| url |
https://doi.org/10.1016/j.biopha.2017.04.022 |
| remote_bool |
true |
| author2 |
Taskapilioglu, Mevlut Ozgur Tunca, Berrin Bekar, Ahmet Demirci, Hilal Kocaeli, Hasan Aksoy, Secil Ak Egeli, Unal Cecener, Gulsah Tolunay, Sahsine |
| author2Str |
Taskapilioglu, Mevlut Ozgur Tunca, Berrin Bekar, Ahmet Demirci, Hilal Kocaeli, Hasan Aksoy, Secil Ak Egeli, Unal Cecener, Gulsah Tolunay, Sahsine |
| ppnlink |
ELV004620771 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.biopha.2017.04.022 |
| up_date |
2024-07-06T16:58:08.526Z |
| _version_ |
1803849656988336128 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV015178218</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625114642.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.biopha.2017.04.022</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000092A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV015178218</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0753-3322(17)30781-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.86</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tezcan, Gulcin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Olea europaea leaf extract and bevacizumab synergistically exhibit beneficial efficacy upon human glioblastoma cancer stem cells through reducing angiogenesis and invasion in vitro</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">11</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Patients with glioblastoma multiforme (GBM) that are cancer stem-cell-positive (GSC [+]) essentially cannot benefit from anti-angiogenic or anti-invasive therapy. In the present study, the potential anti-angiogenic and anti-invasive effects of Olea europaea (olive) leaf extract (OLE) were tested using GSC (+) tumours. OLE (2mg/mL) caused a significant reduction in tumour weight, vascularisation, invasiveness and migration (p =0.0001, p< 0.001, p =0.004; respectively) that was associated with reducing the expression of VEGFA, MMP-2 and MMP-9. This effect was synergistically increased in combination with bevacizumab. Therefore, our current findings may contribute to research on drugs that inhibit the invasiveness of GBM.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">VEGFA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Angiogenesis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMP2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Olea europaea leaf extract</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MMP9</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Invasion</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glioblastoma cancer stem cell</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taskapilioglu, Mevlut Ozgur</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tunca, Berrin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bekar, Ahmet</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Demirci, Hilal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kocaeli, Hasan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Aksoy, Secil Ak</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Egeli, Unal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cecener, Gulsah</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tolunay, Sahsine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Liao, Gary ELSEVIER</subfield><subfield code="t">A Scoping Review of Registered Clinical Trials of Cellular Therapy for COVID-19 and a</subfield><subfield code="d">2020</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV004620771</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:90</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:713-723</subfield><subfield code="g">extent:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.biopha.2017.04.022</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.86</subfield><subfield code="j">Hämatologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">90</subfield><subfield code="j">2017</subfield><subfield code="h">713-723</subfield><subfield code="g">11</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4003067 |